Safety and PK of Inhaled GW642444M with Magnesium Stearate in COPD

Phase 2, randomised, double-blind trial of vilanterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE), Change From Baseline in Hematology Parameters (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, WBC, Hemoglobin, MCHC, Reticulocytes, RBC, Hematocrit, MCV, MCH) and 4 more. Started Aug 2007; status: completed.